Vivoryon Therapeutics N.V. Reports Full Year 2020 Financial Results
Vivoryon Therapeutics Reschedules Reporting of 1st Quarter 2021 and Provides Update for Annual General Meeting of Shareholders
HALLE (SAALE) / MUNICH, GERMANY, May 17, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) invites all shareholders to Vivoryon’s annual general meeting of shareholders to be held on Monday, June 28, 2021 at 10:30 a.m. (CEST).
In accordance with the Temporary Act COVID-19 Justice and Safety (Tijdelijke wet COVID-19 Justitie en Veiligheid) (the COVID Act), shareholders can only attend the meeting virtually through an audio webcast via the company’s website.
All relevant documents are available on the company’s website: https://www.vivoryon.com/ordinary-general-meeting-of-shareholders-2021/
If the duration of COVID Act is not extended beyond May 31, 2021, the annual general meeting will be held on Monday, June 28, 2021 at 10:30 a.m. (CEST) as a hybrid meeting both virtually through an audio webcast via the company’s website, at https://www.vivoryon.com/ordinary-general-meeting-of-shareholders-2021/, and physically at Hilton Amsterdam Airport Schiphol, Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.
For more information, please contact:
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Tel: +49 (0)345 555 99 30
Gretchen Schweitzer / Valeria Fisher
Tel: +49 (0)172 861 8540 or +49 (0)175 8041816
About Vivoryon Therapeutics N.V.
With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon’s scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon is advancing its lead product, varoglutamstat (PQ912), in Alzheimer’s disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. In addition, the company pursues a development program for Meprin protease inhibitors with potential therapeutic use in fibrotic diseases, cancer and acute kidney injury.
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics N.V. as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.